Skip to main content
An official website of the United States government

Special Sources of Funds

Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s).  The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

Download the Data

NCI CRADA Receipts Deposited to the U.S. Treasury
(Dollars in Thousands)
Fiscal Year Carryover from Prior Year Collections Obligations
2006 13,567 6,142 7,125
2007 12,584 9,410 8,360
2008 13,634 6,677 7,200
2009 13,111 5,466 4,765
2010 13,813 5,024 5,644
2011 13,150 8,582 5,894
2012 15,504 9,253 5,668
2013 10,587 11,226 8,470
2014 21,173 9,334 5,672
2015 24,835 15,772 11,670
2016 28,276 23,411 17,259
2017 40,647 27,033 20,990
2018 46,311 28,601 22,936
2019 50,978 32,899 28,178
2020 53,825 33,776 28,683
2021 59,044 38,735 32,994
2022 71,091 22,856 11,301

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years. 

NCI Royalty Income Funding History
(Dollars in Thousands)
Years Collections* Inventor Payments Other Obligations
* Collections do not include assessments by NIH.
** 2021/2023 and 2022/2024 Inventor Payments and Other Obligations are estimates.
1991/1992 $2,084 $431 $1,653
2001/2003 27,443 6,210 21,233
2005/2007 34,086 5,745 28,341
2006/2008 29,811 6,853 22,958
2007/2009 36,344 7,210 29,134
2008/2010 50,269 8,192 42,077
2009/2011 51,621 10,225 41,396
2010/2012 58,515 5,729 52,786
2011/2013 69,155 23,271 45,884
2012/2014 84,876 33,279 51,597
2013/2015 91,324 48,433 42,891
2014/2016 112,668 33,487 79,181
2015/2017 122,037 30,605 91,432
2016/2018 115,096 27,316 87,780
2017/2019 112,611 27,233 85,378
2018/2020 86,231 15,539 70,692
2019/2021 70,400 5,370 65,030
2020/2022 30,850 7,244 23,606
**2021/2023 35,000 8,000 27,000
**2022/2024 35,000 8,000 27,000

Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act (PL 105-41) was enacted in August 1997 and has since been extended to July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), December 2015 (PL 114-99) and recently until December 2027 (PL 116-92). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2022, NCI has received $65,558,428. NCI uses these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In FY 2022, $1,460,509 million in Stamp funds were obligated towards Breast Cancer research.

NCI Breast Cancer Stamp Funding History
(Dollars in Thousands)
FY Collected Obligated *Balance
*Balance includes carryover funds from the prior fiscal year that have not obligated.
1999 4,150 0 4,150
2000 3,101 3,499 3,753
2001 5,556 4,846 4,463
2002 3,595 1,129 6,929
2003 5,176 3,130 8,975
2004 4,814 3,472 10,317
2005 4,372 2,987 11,703
2006 4,468 6,896 9,274
2007 3,006 1,601 10,679
2008 4,856 2,122 13,413
2009 3,403 1,873 14,944
2010 2,345 2,590 14,698
2011 2,049 1,977 14,770
2012 1,623 1,654 14,738
2013 1,404 1,337 14,805
2014 1,160 1,477 14,488
2015 1,251 1,635 14,105
2016 1,707 1,654 14,158
2017 1,387 1,640 13,905
2018 1,294 5,349 16,497
2019 1,450 2,518 15,429
2020 1,060 2,571 13,918
2021 1,112 1,000 14,030
2022 1,221 1,461 13,791
  • Updated:
Email